Sep. 18, 2021

BMS-986242

oral IDO1 inhibitor clinical candidate in Ph. I/II combo for cancer reversed amide of linrodostat ACS Med. Chem. Lett., Jan. 28, 2021 Bristol Myers Squibb, Lawrence Township, NJ

drughunter.com
Drug Hunter Team
Loading...

twitterlinkedinemail

Other molecules you may be interested in